JIN-A02, a Mutant-Selective Fourth-Generation EGFR Inhibitor, Overcomes C797S-Mediated Resistance and Demonstrates...

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have transformed non-small cell lung cancer (NSCLC) treatment for patients with activating EGFR mutations.
• Acquired resistance, particularly the EGFR_C797S mutation, poses a significant clinical challenge, limiting treatment options after third-generation EGFR-TKI failure.

Purpose of the Study:

• To evaluate JIN-A02, a novel fourth-generation EGFR-TKI, as a potential therapeutic strategy.
• To assess JIN-A02's ability to overcome EGFR_C797S-mediated resistance in NSCLC.

Main Methods:

• Preclinical evaluation of JIN-A02's antitumor efficacy and blood-brain barrier penetration.
• In vitro and in vivo studies using NSCLC models with EGFR_C797S and T790M mutations.

Main Results:

• JIN-A02 exhibited potent antiproliferative activity and superior inhibition of EGFR signaling compared to osimertinib in preclinical models.
• Significant tumor regression was observed in both subcutaneous and intracranial xenograft models, demonstrating robust in vivo efficacy.
• Early clinical data indicated promising signs of efficacy, with 3 patients achieving partial response. The agent was well-tolerated.

Conclusions:

• JIN-A02 represents a promising therapeutic strategy for overcoming C797S- and T790M-mediated resistance in EGFR-mutant NSCLC.
• The findings support the further clinical development of JIN-A02, including for intracranial disease.